ProfileGDS5678 / 1417278_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 61% 59% 59% 57% 55% 63% 60% 59% 59% 58% 62% 60% 59% 59% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6651561
GSM967853U87-EV human glioblastoma xenograft - Control 23.546459
GSM967854U87-EV human glioblastoma xenograft - Control 33.5458459
GSM967855U87-EV human glioblastoma xenograft - Control 43.4157557
GSM967856U87-EV human glioblastoma xenograft - Control 53.313755
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8488963
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6960960
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5354159
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5220659
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4968658
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6905862
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5401860
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5526259
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5416159